wave
life
sciences
highlight
preclinical
adar
editing
data
neurology
programs
tides
ots
annual
meetings
cambridge
globe
newswire
wave
life
sciences
nasdaq
wve
genetic
medicines
company
committed
delivering
treatments
people
battling
devastating
diseases
announced
today
highlight
adar
adenosine
deaminases
acting
rna
rna
editing
technology
adar
editing
neurology
programs
huntington
disease
hd
amyotrophic
lateral
sclerosis
als
frontotemporal
dementia
ftd
upcoming
conferences
including
tides
oligonucleotide
peptide
therapeutics
meeting
annual
meeting
oligonucleotide
therapeutics
society
ots
taking
place
september
september
respectively
tides
ots
wave
share
developing
adar
editing
potentially
rna
editing
approach
applicability
across
multiple
genetic
diseases
notably
one
wave
presentations
tides
include
company
first
adar
editing
data
ex
vivo
retina
samples
primates
nhps
data
add
growing
body
vitro
vivo
data
company
generated
include
editing
liver
nhps
central
nervous
system
humanized
mouse
model
support
adar
editing
emerging
platform
capability
wave
another
presentation
tides
highlight
wave
neurology
pipeline
including
silencing
program
als
ftd
well
program
hd
expected
initiate
clinical
development
submission
clinical
trial
applications
fourth
quarter
details
data
presentations
tides
oligonucleotide
peptide
therapeutics
meeting
stereopure
oligonucleotides
produce
potent
durable
activity
eye
supporting
development
inherited
retinal
diseases
presentation
michael
byrne
phd
director
vivo
biology
ophthalmology
wave
life
sciences
provide
update
applying
company
prismtm
platform
develop
stereopure
oligonucleotides
potential
treatment
inherited
retinal
diseases
panel
discussion
preclinical
clinical
development
oligonucleotides
tuesday
september
et
demand
presentation
track
oligonucleotide
discovery
preclinical
clinical
stereopure
oligonucleotides
development
treatment
genetically
defined
diseases
presentation
michael
panzara
md
mph
chief
medical
officer
head
therapeutics
discovery
development
wave
life
sciences
provide
overview
wave
neurology
pipeline
including
stereopure
oligonucleotides
hd
well
preclinical
silencing
program
als
ftd
demand
presentation
track
oligonucleotide
discovery
preclinical
clinical
annual
meeting
oligonucleotide
therapeutics
society
stereopure
oligonucleotides
support
efficient
rna
editing
primates
presentation
chikdu
shivalila
phd
senior
scientist
ii
biology
wave
life
sciences
provide
overview
wave
adar
editing
modality
uses
oligonucleotides
elicit
rna
base
editing
endogenous
adar
enzymes
particular
focus
company
vivo
study
liver
nhps
short
talk
session
ix
preclinical
results
available
demand
prism
wave
life
sciences
proprietary
discovery
drug
development
platform
enables
genetically
defined
diseases
targeted
stereopure
oligonucleotides
across
multiple
therapeutic
modalities
including
silencing
splicing
editing
prism
combines
company
unique
ability
construct
stereopure
oligonucleotides
deep
understanding
interplay
among
oligonucleotide
sequence
chemistry
backbone
stereochemistry
impacts
key
pharmacological
properties
exploring
interactions
iterative
analysis
vitro
vivo
outcomes
machine
predictive
modeling
company
continues
define
design
principles
deployed
across
programs
rapidly
develop
manufacture
clinical
candidates
meet
product
profiles
wave
life
sciences
wave
life
sciences
nasdaq
wve
genetic
medicines
company
committed
delivering
treatments
people
battling
devastating
diseases
wave
aspires
develop
medicines
across
multiple
therapeutic
modalities
using
prism
company
proprietary
discovery
drug
development
platform
enables
precise
design
optimization
production
stereopure
oligonucleotides
driven
resolute
sense
urgency
wave
team
targeting
broad
range
genetically
defined
diseases
patients
families
may
realize
brighter
future
find
please
visit
follow
wave
twitter
wavelifesci
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
amended
including
without
limitation
development
adar
editing
potentially
rna
editing
approach
emerging
platform
capability
wave
potential
wave
preclinical
data
including
data
neurology
programs
huntington
disease
hd
amyotrophic
lateral
sclerosis
als
frontotemporal
dementia
ftd
expected
timing
initiation
clinical
development
wave
silencing
program
als
ftd
well
program
hd
words
may
could
would
expect
plan
anticipate
intend
believe
estimate
predict
project
potential
continue
target
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
press
release
based
management
current
expectations
beliefs
subject
number
risks
uncertainties
important
factors
may
cause
actual
events
results
differ
materially
expressed
implied
statements
contained
press
release
including
without
limitation
risks
uncertainties
described
section
entitled
risk
factors
wave
recent
annual
report
form
filed
securities
exchange
commission
sec
amended
filings
wave
makes
sec
time
time
wave
undertakes
obligation
update
information
contained
press
release
reflect
subsequently
occurring
events
circumstances
investor
contacts
kate
rausch
krausch
graham
morrell
gmorrell
